The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of panc…
Injectable Medication
FDA to Review NDA for Lixisenatide, Sanofi’s New Type 2 Diabetes Therapy
The FDA has accepted Sanofi's New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor …
Lyxumia, Sanofi’s Type 2 Diabetes Treatment, Approved in EU
The European Commission has granted Marketing Authorisation in Europe for Sanofi's new type 2 diabetes treatment, Lyxum…
Zealand Pharma Begins Phase 1 Study of Type 2 Diabetes Drug
Zealand Pharma, a Danish biotechnology company dedicated to the discovery and development of innovative peptide drugs, a…
FDA approves Lucentis for Diabetic Macular Edema
The U.S. FDA has approved Roche's Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a …
Novo Nordisk to Begin Phase 3 Development of Semaglutide for Type 2 Diabetes
Semaglutide successfully completed phase 2 development in 2010. At that time, it was decided to compare semaglutide with…
New Observational Data Shows Patients Prefer Victoza
New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of H…
Sanofi Presents New Data on Lixisenatide, an Investigational GLP-1 Agonist, for Type 2 Diabetes
Sanofi has presented data from two studies demonstrating Lyxumia (lixisenatide), a once-daily investigational GLP-1 agon…
The Significance of the Victoza Product Label Update
Novo Nordisk’s widely popular GLP-1 analog Victoza made headlines at the beginning of the year when celebrity chef…
EU Approves Type 2 Diabetes Drug Byetta for Use with Basal Insulin
The European Commission has granted marketing authorization to Byetta (exenatide twice-daily) as an adjunctive therapy t…